Docetaxel with prednisone or prednisolone for the treatment of ...

146
Appendix 6
Study details and Participant details Intervention details Results Conclusion and
design comments
Mood:
LASA best changes (p = 0.02)
Data from Osoba et al.: 46
Data given for 3 groups – I, C after 6 weeks and crossover
from C to I after 6 weeks
I: (n = 71) improvements compared with baseline in physical
functioning, social functioning, global QoL, pain, anorexia,
constipation, impact of pain on mobility, degree of pain relief,
drowsiness (0.0001 < p < 0.009)
Increased alopecia was only significant negative effect
(p = 0.009)
After 4 cycles (n = 54) continued improvement in 4
functioning scores (0.0001 < p < 0.004), global QoL
(p = 0.009) and 9 symptoms (0.0001 < p < 0.01), alopecia
showed continued deterioration (p = 0.001)
After 6 cycles (n = 43) showed continued improvement in
11 of 14 scales showing improvement after 4 cycles
Duration of improvements ranged from 11 to 19 weeks
C: (n = 62) improvements compared with baseline in social
functioning, global QoL, nausea and vomiting, anorexia
(0.003 < p < 0.007) and impact of pain on mobility
(p = 0.01). After 4 cycles (n = 42) no measure showed
significant difference from baseline
After 6 cycles (n = 19) only impact of pain on mobility was
better than baseline (p = 0.004)
Duration of improvements ranged from 3 to 7 weeks
Crossover group (n = 35) after 6 weeks (2 cycles) of I had
improvements in pain, insomnia and impact of pain on
mobility (0.0001 < p < 0.01)
After 4 cycles (n = 25) there was improved global QoL
(p = 0.003) and pain relief (p = 0.0001)
After 6 cycles (n = 17) improved pain, impact of pain on
mobility and pain relief (0.001 < p < 0.003), but greater
alopecia (p = 0.01)
Duration of improvement ranged from 4 to 26 weeks
continued